Download Files:
Products Details
Product Description
– YLT-11 is a potent, selective and orally active PLK4 inhibitor with Kd values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity[1].
Web ID
– HY-115589
Shipping
– Room temperature
Molecular Formula
– C24H24N6O
References
– [1]Lei Q, et al. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death Dis. 2018 Oct 18;9(11):1066.
Molecular Weight
– 412.49
SMILES
– CC(NC1=NC=CC(C2=CC3=C(C=C2)C(/C=C/C4=CC=C(CN(C)C)C=C4)=NN3)=N1)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;Polo-like Kinase (PLK)
Isoform
– PLK1;PLK2;PLK3;PLK4
Pathway
– Apoptosis;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
